Skip to main content

Products & Services: Oct 15, 2009

Premium

Prometheus Laboratories has launched three microRNA-based diagnostics: ProOnc TumorSource Dx, ProOnc Squamous Dx, and ProOnc Mesothelioma Dx.

According to the company, the first identifies the tissue-of-origin of a metastatic tumor; the second classifies non-small cell lung carcinoma tumors into two histological groups: cancers of squamous histology and non-squamous cancers; and the third differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.

The tests were formerly known as miRview Mets, miRview Squamous, and miRview Meso, and were developed by Rosetta Genomics. In April, Rosetta agreed to license the US rights to the products to Prometheus (see RNAi News, 4/16/2009). The deal closed a few weeks later.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.